ATE521631T1 - Verwendung von aimp2dx2 zur diagnose und behandlung von krebs - Google Patents

Verwendung von aimp2dx2 zur diagnose und behandlung von krebs

Info

Publication number
ATE521631T1
ATE521631T1 AT05819055T AT05819055T ATE521631T1 AT E521631 T1 ATE521631 T1 AT E521631T1 AT 05819055 T AT05819055 T AT 05819055T AT 05819055 T AT05819055 T AT 05819055T AT E521631 T1 ATE521631 T1 AT E521631T1
Authority
AT
Austria
Prior art keywords
aimp2dx2
diagnose
treat cancer
aimp2
cancer
Prior art date
Application number
AT05819055T
Other languages
English (en)
Inventor
Sunghoon Kim
Original Assignee
Neomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomics Co Ltd filed Critical Neomics Co Ltd
Priority claimed from PCT/KR2005/003924 external-priority patent/WO2006057500A1/en
Application granted granted Critical
Publication of ATE521631T1 publication Critical patent/ATE521631T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023Lung
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05819055T 2004-11-24 2005-11-18 Verwendung von aimp2dx2 zur diagnose und behandlung von krebs ATE521631T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040097164 2004-11-24
KR1020050039073A KR20060057992A (ko) 2004-11-24 2005-05-10 p38-DX2 및 이의 용도
PCT/KR2005/003924 WO2006057500A1 (en) 2004-11-24 2005-11-18 Use of aimp2dx2 for the diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
ATE521631T1 true ATE521631T1 (de) 2011-09-15

Family

ID=37153221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819055T ATE521631T1 (de) 2004-11-24 2005-11-18 Verwendung von aimp2dx2 zur diagnose und behandlung von krebs

Country Status (5)

Country Link
JP (1) JP4718556B2 (de)
KR (1) KR20060057992A (de)
CN (1) CN101087804B (de)
AT (1) ATE521631T1 (de)
ES (1) ES2371479T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ, インコーポレイテッド p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2014111553A1 (de) * 2013-01-17 2014-07-24 Sit Soft Intelligent Therapeutics Gmbh & Co Kg Selektives zelltod-induzierendes binäres enzymsystem
KR102297505B1 (ko) * 2016-03-07 2021-09-01 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
EP3375871A1 (de) 2017-03-13 2018-09-19 SIT Biotech GmbH Enzymsystem zur auslösung von selektivem zelltod
US10716866B2 (en) 2018-03-29 2020-07-21 Generoath Co., Ltd Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터
WO2022054999A1 (ko) * 2020-09-14 2022-03-17 주식회사 제너로스 생착능이 증가된 줄기세포의 제조 방법
WO2022070142A1 (en) * 2020-09-30 2022-04-07 Generoath Co., Ltd. METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100575251B1 (ko) * 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법

Also Published As

Publication number Publication date
KR20060057992A (ko) 2006-05-29
JP2008521398A (ja) 2008-06-26
CN101087804B (zh) 2012-07-04
CN101087804A (zh) 2007-12-12
ES2371479T3 (es) 2012-01-03
JP4718556B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EP1888786A4 (de) Verwendung freier zirkulierender dna zur diagnose, prognose und behandlung von krebs
ATE295735T1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
DE602006017071D1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
ATE399014T1 (de) Nukleinsäuren zur behandlung von erkrankungen im zusammenhang mit hmgb1
EP1742675A4 (de) Behandlung von biomedizinischem abfall
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE502006007963D1 (de) Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen
ATE521631T1 (de) Verwendung von aimp2dx2 zur diagnose und behandlung von krebs
EP1869212A4 (de) Verwendung von id4 zur diagnose und behandlung von krebs
ATE501718T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
ATE465413T1 (de) Verwendung von adam 12 zur diagnose von präeklampsie
DE602005023468D1 (de) Verwendung von zahnfleischfibroblasten zur behandlung von vaskulären zellen
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties